Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Neurosurg Rev. 2014 Apr;37(2):279-85; discussion 285-6. doi: 10.1007/s10143-014-0525-y. Epub 2014 Feb 14.
Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until identification of metastases. Optimal management and survival outcomes for both are not clearly defined. The purpose of this study is to use the Surveillance, Epidemiology, and End Results (SEER) database to report patterns of care and compare survival outcomes in a large series of patients with invasive adenomas or pituitary carcinomas. One hundred seventeen patients diagnosed between 1973 and 2008 with pituitary adenomas/adenocarcinomas were included. Eighty-three invasive adenomas and seven pituitary carcinomas were analyzed for survival outcomes. Analyzed prognostic factors included age, sex, race, histology, tumor extent, and treatment. A significant decrease in survival was observed among carcinomas compared to invasive adenomas at 1, 2, and 5 years (p = 0.047, 0.001, and 0.009). Only non-white race, male gender, and age ≥65 were significant negative prognostic factors for invasive adenomas (p = 0.013, 0.033, and <0.001, respectively). There was no survival advantage to radiation therapy in treating adenomas at 5, 10, 20, or 30 years (p = 0.778, 0.960, 0.236, and 0.971). In conclusion, pituitary carcinoma patients exhibit worse overall survival than invasive adenoma patients. This highlights the need for improved diagnostic methods for the sellar phase to allow for potentially more aggressive treatment approaches.
侵袭性垂体腺瘤和垂体腺癌在未发现转移灶之前临床难以区分。目前尚未明确这两种肿瘤的最佳治疗方法和生存结局。本研究旨在利用监测、流行病学和最终结果(SEER)数据库报告一组侵袭性垂体腺瘤或垂体腺癌患者的治疗模式,并比较其生存结局。共纳入 1973 年至 2008 年间诊断为垂体腺瘤/腺癌的 117 例患者。对 83 例侵袭性垂体腺瘤和 7 例垂体腺癌患者的生存结局进行分析。分析的预后因素包括年龄、性别、种族、组织学、肿瘤范围和治疗方法。与侵袭性垂体腺瘤相比,腺癌患者在 1、2 和 5 年的生存率显著降低(p=0.047、0.001 和 0.009)。非白人种族、男性和年龄≥65 岁是侵袭性垂体腺瘤的显著负性预后因素(p=0.013、0.033 和<0.001)。在 5、10、20 和 30 年时,放射治疗对治疗侵袭性垂体腺瘤并没有生存优势(p=0.778、0.960、0.236 和 0.971)。总之,垂体腺癌患者的总体生存率明显低于侵袭性垂体腺瘤患者。这突出表明需要改进鞍区诊断方法,以便能够采取更积极的治疗方法。